# Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

> **NCT03573648** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 33 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Endocrine therapy
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03573648
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-13
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573648, "Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03573648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*